title: IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs.
abstract: Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial. The addition of this drug makes a ménage à trois of available drugs--comprising infliximab, adalimumab and golimumab--for the treatment of ulcerative colitis.
authors.affiliation: IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Centre, Via Manzoni 56, 20089 Rozzano, Milan, Italy. sdanese@hotmail.com.
authors.forename: Silvio
authors.initials: S
authors.lastname: Danese
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab
references.citation: J Crohns Colitis. 2008 Sep;2(3):219-25
references.pmid: 21172214
references.citation: Gastroenterology. 2014 Jan;146(1):96-109.e1
references.pmid: 23770005
references.citation: Aliment Pharmacol Ther. 2013 May;37(9):855-66
references.pmid: 23489068
references.citation: Am J Gastroenterol. 2010 Dec;105(12):2617-25
references.pmid: 20736936
references.citation: Inflamm Bowel Dis. 2013 Apr;19(5):1065-72
references.pmid: 23448790
references.citation: Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5
references.pmid: 23735746
references.citation: Gastroenterology. 2009 Oct;137(4):1250-60; quiz 1520
references.pmid: 19596014